查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1869757

藥物重定位市場規模、佔有率和趨勢分析報告：按治療領域、藥物類型、最終用途、地區和細分市場預測（2025-2033 年）

Drug Repurposing Market Size, Share & Trends Analysis Report By Disease Area (Oncology, Neurology Disorders, Infectious Diseases, Cardiovascular Conditions, Metabolic Disorders), By Drug Type, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

藥物重定位市場摘要

2024年全球藥物重定位市場規模估計為329.6億美元，預計2033年將達474億美元。

預計從2025年到2033年，該市場將以4.12%的複合年成長率成長。由於該市場有潛力為製藥公司提供經濟高效且省時的解決方案，因此備受關注。

推動這一成長的關鍵因素在於能夠利用已確立安全性特徵的現有藥物，這顯著減少了耗時的臨床前試驗和早期臨床開發的需求。例如，2023年9月，美國食品藥物管理局（FDA）批准了Empagliflozin（Jardiance），這是一種最初為治療第2型糖尿病而開發的藥物，用於治療有進展核准的成人慢性腎臟病（CKD），無論是否患有糖尿病。

由勃林格殷格翰和禮來公司聯合研發的Empagliflozin）在臨床試驗中展現出令人鼓舞的結果，可降低慢性腎臟病（CKD）患者腎功能下降、腎衰竭、心血管死亡和心臟衰竭住院的風險。該藥物最初核准用於治療第2型糖尿病，此次核准使其應用範圍擴展至糖尿病治療之外，也反映了將現有藥物用於治療選擇有限的疾病日益成長的趨勢。這項進展凸顯了人們對藥物再利用的日益成長的支持，以及利用現有藥物開發新適應症的顯著益處。

此外，慢性病和罕見病患疾病率的不斷上升是仿單標示外使用的主要因素。例如，2022年12月，FDA核准Cariprazine（商品名Vraylar）作為輔助治療藥物，用於治療對抗抗憂鬱症療效不佳的成人重度憂鬱症（MDD）。Cariprazine最初由吉瑞製藥（Gedeon Richter）研發，並於2015年首次核准FDA批准，用於治療思覺失調症和I型雙相情感障礙。艾伯維（AbbVie）於2020年透過收購艾爾建（Allergan）獲得了Cariprazine的權益。此次核准Vraylar獲準的第四項適應症，也印證了將現有藥物重新用於治療治療選擇有限的疾病日益成長的趨勢。

2023年3月，美國食品藥物管理局（FDA）批准了最初用於核准活化磷脂-3-激酶Delta症候群（APDS）的藥物leniolisib（商品名Joenja），用於治療活化PI3Kδ症候群，這是一種罕見的免疫疾病。 Leniolisib是一種選擇性PI3Kδ酶抑制劑，PI3Kδ酶在免疫細胞功能中發揮關鍵作用。 Leniolisib的核准凸顯了將現有藥物重新用於治療罕見疾病和孤兒病的趨勢日益成長，因為在這些疾病中，開發新藥既耗時又難以實現成本效益。這項策略性舉措表明，人們越來越支持藥物重新用於治療方法的開發。

輝瑞一直積極致力於透過藥物再利用來推廣前列腺癌的治療。 2021年7月，輝瑞與Albinus Therapeutics達成一項全球共同開發契約，共同開發和商業化ARV-471，這是一種口服PROTAC®（蛋白水解靶向嵌合體）雌激素受體蛋白分解劑。此次合作旨在利用現有療法來應對複雜且治療不足的癌症，這與輝瑞拓展其腫瘤產品組合的整體策略一致。此外，2024年4月，Albinus Therapeutics與諾華達成一項許可和資產出售協議，共同開發和商業化ARV-766，這是一種正在開發用於治療前列腺癌的第二代雄激素受體分解劑。該協議總價值超過10億美元，顯示各方對透過現有藥物再利用來拓展前列腺癌治療方案的興趣和投資日益成長。

2025年1月，拜耳向美國食品藥物管理局（FDA）提交了一份補充新藥申請（sNDA），旨在擴大凱倫迪亞（Kelendia）的核准，使其涵蓋左心室心臟衰竭（ HF）患者，包括輕度射血分數降低的心臟衰竭患者的心臟衰竭和新藥認證患者的心臟衰竭（HFpEF）。 FDA受理了該申請並授予優先審查資格。 2025年7月14日，FDA在完成對該sNDA的優先審查後，核准了這項新適應症。

目錄

第1章調查方法和範圍

第2章執行摘要

3. 藥物重定位市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析

第4章：藥物重定位市場：依治療領域分類的業務分析

  • 按治療領域分類的市場佔有率，2024 年和 2033 年
  • 治療領域細分儀表板
  • 全球藥物重定位市場規模、預測與趨勢分析（按治療領域分類，2021-2033 年）
  • 腫瘤學
  • 神經系統疾病
  • 感染疾病
  • 心血管疾病
  • 代謝紊亂
  • 其他治療領域

第5章 藥物重定位市場：依藥物類型分類的業務分析

  • 按藥物類型分類的市場佔有率，2024 年和 2033 年
  • 藥物類型細分儀表板
  • 全球藥物重定位市場規模、預測與趨勢分析（按藥物類型分類，2021-2033 年）
  • 傳統小分子
  • 生技藥品和胜肽類藥物

第6章 藥品再利用市場：依最終用途分類的業務分析

  • 按最終用途分類的市場佔有率，2024 年和 2033 年
  • 最終用戶細分儀表板
  • 全球藥物重定位市場規模、預測與趨勢分析（按最終用途分類，2021-2033 年）
  • 生物製藥和製藥公司
  • 臨床研究機構（CRO）
  • 大學和研究機構

第7章 藥物重定位市場：區域估算與趨勢分析

  • 2024 年及 2033 年區域市佔率分析
  • 區域市場概覽
  • 全球藥物重定位市場規模及預測趨勢分析（2021-2033）：
  • 北美洲
    • 按國家/地區分類，2021-2033 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭情勢

  • 參與企業概況
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介
    • Eli Lilly and Company
    • Pfizer Inc.
    • Roche Holding AG
    • Novartis AG
    • Bayer AG
    • GSK plc
    • Amgen Inc.
    • Biogen Inc.
    • Teva Pharmaceutical
    • Vertex Pharmaceuticals
Product Code: GVR-4-68040-760-1

Drug Repurposing Market Summary

The global drug repurposing market size was estimated at USD 32.96 billion in 2024 and is projected to reach USD 47.40 billion by 2033, growing at a CAGR of 4.12% from 2025 to 2033. The market has gained significant traction, driven by the potential to offer both cost-effective and time-efficient solutions for pharmaceutical companies.

A critical driver of this growth is the opportunity to leverage existing drugs with well-established safety profiles, significantly reducing the need for lengthy preclinical trials and early-phase clinical development. For instance, in September 2023, the FDA approved empagliflozin (brand name Jardiance), a medication originally developed for type 2 diabetes, for the treatment of chronic kidney disease (CKD) in adults at risk of progression, regardless of diabetes status.

Empagliflozin, developed by Boehringer Ingelheim and Eli Lilly, has shown promising results in clinical trials for reducing the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in CKD patients. While initially approved for type 2 diabetes, this approval extends its potential beyond diabetes management, demonstrating the growing trend of repurposing existing drugs for conditions with limited treatment options. This move highlights the increasing support for drug repurposing efforts and the significant benefits of leveraging established medications for new therapeutic indications.

Furthermore, the rising prevalence of chronic and rare diseases has significantly contributed to the push for repurposed drugs. For example, in December 2022, the FDA approved cariprazine (brand name Vraylar) as an adjunctive treatment for major depressive disorder (MDD) in adults who have had an inadequate response to antidepressant therapy. Cariprazine was originally developed by Gedeon Richter and was first approved by the FDA in 2015 for the treatment of schizophrenia and bipolar I disorder. AbbVie acquired the rights to cariprazine through its acquisition of Allergan in 2020. This approval marks the fourth indication for Vraylar, underscoring the growing trend of repurposing existing medications to address conditions with limited treatment options.

In March 2023, the FDA approved leniolisib (brand name Joenja), a medication originally developed for activated phosphoinositide 3-kinase delta syndrome (APDS), for the treatment of activated PI3K delta syndrome, a rare immune disorder. Leniolisib is a selective inhibitor of the PI3Kδ enzyme, which plays a crucial role in immune cell function. The approval of leniolisib highlights the growing trend of repurposing existing drugs to address rare and orphan diseases, where the development of new drugs can be cost-prohibitive and time-consuming. This strategic move underscores the increasing support for drug repurposing efforts to encourage the development of treatments for conditions with limited therapeutic options.

In drug repurposing, Pfizer has been actively engaged in advancing treatments for prostate cancer. In July 2021, Pfizer entered into a global collaboration with Arvinas to co-develop and co-commercialize ARV-471, an investigational oral PROTAC(R) (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. This partnership aims to leverage existing treatments to address complex and underserved cancers, aligning with Pfizer's broader strategy to expand its oncology portfolio. Additionally, in April 2024, Arvinas entered into a separate licensing and asset-sale agreement with Novartis, valued at over USD 1 billion, for the development and commercialization of ARV-766, a second-generation androgen receptor degrader for prostate cancer. This move underscores the growing interest and investment in repurposing existing drugs to enhance treatment options for prostate cancer patients.

In January 2025, Bayer submitted an sNDA to the U.S. Food and Drug Administration (FDA) seeking approval for Kerendia to treat adult patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) of >=40%, including both mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF). The FDA accepted the application and granted Priority Review designation. The FDA approved this new indication on July 14, 2025, following the agency's Priority Review of its supplemental New Drug Application (sNDA

Global Drug Repurposing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global drug repurposing market report based on Disease Area, drug type, end use, and region :

  • Disease Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Neurology Disorders
  • Infectious Diseases
  • Cardiovascular Conditions
  • Metabolic Disorders
  • Others Therapeutic Areas
  • Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Conventional Small Molecules
  • Biologics and Peptide-based Drugs
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Biopharmaceutical & Pharmaceutical Companies
  • Clinical Research Organizations (CROs)
  • Universities & Research Institutions
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease Area
    • 1.2.2. Drug Type
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Drug Repurposing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Drug Repurposing Market: Disease Area Business Analysis

  • 4.1. Disease Area Market Share, 2024 & 2033
  • 4.2. Disease Area Segment Dashboard
  • 4.3. Global Drug Repurposing Market Size & Forecasts and Trend Analysis, by Disease Area, 2021 to 2033 (USD Million)
  • 4.4. Oncology
    • 4.4.1. Oncology Market, 2021 - 2033 (USD Million)
  • 4.5. Neurology Disorders
    • 4.5.1. Neurology Disorders Market, 2021 - 2033 (USD Million)
  • 4.6. Infectious Diseases
    • 4.6.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
  • 4.7. Cardiovascular Conditions
    • 4.7.1. Cardiovascular Conditions Market, 2021 - 2033 (USD Million)
  • 4.8. Metabolic Disorders
    • 4.8.1. Metabolic Disorders Market, 2021 - 2033 (USD Million)
  • 4.9. Others Therapeutic Areas
    • 4.9.1. Others Therapeutic Areas Market, 2021 - 2033 (USD Million)

Chapter 5. Drug Repurposing Market: Drug Type Business Analysis

  • 5.1. Drug Type Market Share, 2024 & 2033
  • 5.2. Drug Type Segment Dashboard
  • 5.3. Global Drug Repurposing Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
  • 5.4. Conventional Small Molecules
    • 5.4.1. Conventional Small Molecules Market, 2021 - 2033 (USD Million)
  • 5.5. Biologics and Peptide-based Drugs
    • 5.5.1. Biologics and Peptide-based Drugs Market, 2021 - 2033 (USD Million)

Chapter 6. Drug Repurposing Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2024 & 2033
  • 6.2. End Use Segment Dashboard
  • 6.3. Global Drug Repurposing Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 6.4. Biopharmaceutical & Pharmaceutical Companies
    • 6.4.1. Biopharmaceutical & Pharmaceutical Companies Market, 2021 - 2033 (USD Million)
  • 6.5. Clinical Research Organizations (CROs)
    • 6.5.1. Clinical Research Organizations (CROs) Market, 2021 - 2033 (USD Million)
  • 6.6. Universities & Research Institutions
    • 6.6.1. Universities & Research Institutions Market, 2021 - 2033 (USD Million)

Chapter 7. Drug Repurposing Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Global Drug Repurposing Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Drug Repurposing Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Reimbursement Framework
      • 7.4.2.4. U.S. Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Reimbursement Framework
      • 7.4.3.4. U.S. Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Reimbursement Framework
      • 7.4.4.4. Mexico Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Reimbursement Framework
      • 7.5.2.4. UK Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Reimbursement Framework
      • 7.5.3.4. Germany Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Reimbursement Framework
      • 7.5.4.4. France Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Reimbursement Framework
      • 7.5.5.4. Italy Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Reimbursement Framework
      • 7.5.6.4. Spain Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Reimbursement Framework
      • 7.5.7.4. Denmark Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Reimbursement Framework
      • 7.5.8.4. Sweden Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Reimbursement Framework
      • 7.5.9.4. Norway Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Reimbursement Framework
      • 7.6.2.4. Japan Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Reimbursement Framework
      • 7.6.4.4. India Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Reimbursement Framework
      • 7.6.5.4. Australia Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Reimbursement Framework
      • 7.6.6.4. South Korea Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Reimbursement Framework
      • 7.6.7.4. Thailand Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Reimbursement Framework
      • 7.7.2.4. Japan Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Reimbursement Framework
      • 7.7.3.4. China Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Reimbursement Framework
      • 7.8.2.4. South Africa Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Reimbursement Framework
      • 7.8.3.4. Saudi Arabia Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Reimbursement Framework
      • 7.8.4.4. UAE Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Reimbursement Framework
      • 7.8.5.4. Kuwait Drug Repurposing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Eli Lilly and Company
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Pfizer Inc.
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Roche Holding AG
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Novartis AG
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Bayer AG
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. GSK plc
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Amgen Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Biogen Inc.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Teva Pharmaceutical
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Vertex Pharmaceuticals
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global drug repurposing market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 5 Global drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 6 Global drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 7 North America drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 9 North America drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 10 North America drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 11 U.S drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 12 U.S drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 13 U.S drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 14 Canada drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 15 Canada drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 16 Canada drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 17 Mexico drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 18 Mexico drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 19 Mexico drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 20 Europe drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 22 Europe drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 23 Europe drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 24 UK drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 25 UK drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 26 UK drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 27 Germany drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 28 Germany drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 29 Germany drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 30 France drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 31 France drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 32 France drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 33 Italy drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 34 Italy drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 35 Italy drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 36 Spain drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 37 Spain drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 38 Spain drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 39 Norway drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 40 Norway drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 41 Norway drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 42 Denmark drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 43 Denmark drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 44 Denmark drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 45 Sweden drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 46 Sweden drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 47 Sweden drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific drug repurposing market, by drug type , 2021-2033, (USD
  • Table 51 Asia Pacific drug repurposing market, by end use , 2021-2033, (USD Million)
  • Table 52 Japan drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 52 Japan drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 54 Japan drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 55 China drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 56 China drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 57 China drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 58 India drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 69 India drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 70 India drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 71 Australia drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 72 Australia drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 73 Australia drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 74 South Korea drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 75 South Korea drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 76 South Korea drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 77 Thailand drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 78 Thailand drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 89 Thailand drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 80 Latin America drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 81 Latin America drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 82 Latin America drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 83 Latin America drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 84 Brazil drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 85 Brazil drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 86 Brazil drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 87 Argentina drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 88 Argentina drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 89 Argentina drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 90 Middle East & Africa Drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 91 Middle East & Africa drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 92 Middle East & Africa drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 93 Middle East & Africa drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 94 South Africa drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 95 South Africa drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 96 South Africa drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 97 Saudi Arabia drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 98 Saudi Arabia drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 99 Saudi Arabia drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 100 UAE drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 101 UAE drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 102 UAE drug repurposing market, by end use , 2021 - 2033 (USD Million)
  • Table 103 Kuwait drug repurposing market, by disease area, 2021 - 2033 (USD Million)
  • Table 104 Kuwait drug repurposing market, by drug type , 2021 - 2033 (USD Million)
  • Table 105 Kuwait drug repurposing market, by end use , 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Drug repurposing market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and disease area outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Drug repurposing market dynamics
  • Fig. 12 Drug repurposing market: Porter's five forces analysis
  • Fig. 13 Drug repurposing market: PESTLE analysis
  • Fig. 14 Oncology market, 2021 - 2033 (USD Million)
  • Fig. 15 Neurology Disorders market, 2021 - 2033 (USD Million)
  • Fig. 16 Infectious Diseases market, 2021 - 2033 (USD Million)
  • Fig. 17 Cardiovascular Conditions market, 2021 - 2033 (USD Million)
  • Fig. 18 Metabolic Disorders market, 2021 - 2033 (USD Million)
  • Fig. 19 Others Therapeutic Areas market, 2021 - 2033 (USD Million)
  • Fig. 20 Drug Type market, 2021 - 2033 (USD Million)
  • Fig. 21 Conventional Small Molecules market, 2021 - 2033 (USD Million)
  • Fig. 22 Biologics and Peptide-based Drugs market, 2021 - 2033 (USD Million)
  • Fig. 23 End Use market, 2021 - 2033 (USD Million)
  • Fig. 24 Biopharmaceutical & Pharmaceutical Companies market, 2021 - 2033 (USD Million)
  • Fig. 25 Clinical Research Organizations (CROs) market, 2021 - 2033 (USD Million)
  • Fig. 26 Universities & Research Institutions market, 2021 - 2033 (USD Million)
  • Fig. 27 Drug repurposing market revenue, by region
  • Fig. 28 Regional marketplace: Key takeaways
  • Fig. 29 North America drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 30 U.S. country dynamics
  • Fig. 31 U.S. drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 32 Canada country dynamics
  • Fig. 33 Canada drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 34 Mexico country dynamics
  • Fig. 35 Mexico drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 36 Europe drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 37 UK country dynamics
  • Fig. 38 UK drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 39 Germany country dynamics
  • Fig. 40 Germany drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 41 France country dynamics
  • Fig. 42 France drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 43 Italy country dynamics
  • Fig. 44 Italy drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 45 Spain country dynamics
  • Fig. 46 Spain drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 47 Norway country dynamics
  • Fig. 48 Norway drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 49 Sweden country dynamics
  • Fig. 50 Sweden drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 51 Denmark country dynamics
  • Fig. 52 Denmark drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 53 Asia Pacific drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 54 Japan country dynamics
  • Fig. 55 Japan drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 56 China country dynamics
  • Fig. 57 China drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 58 India country dynamics
  • Fig. 59 India drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 60 Australia country dynamics
  • Fig. 61 Australia drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 62 South Korea country dynamics
  • Fig. 63 South Korea drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 64 Thailand country dynamics
  • Fig. 65 Thailand drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 66 Latin America drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 67 Brazil country dynamics
  • Fig. 68 Brazil drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 69 Argentina country dynamics
  • Fig. 70 Argentina drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 71 Middle East and Africa drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 72 South Africa country dynamics
  • Fig. 73 South Africa drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 74 Saudi Arabia country dynamics
  • Fig. 75 Saudi Arabia drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 76 UAE country dynamics
  • Fig. 77 UAE drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 78 Kuwait country dynamics
  • Fig. 79 Kuwait drug repurposing market, 2021 - 2033 (USD Million)
  • Fig. 80 Company categorization
  • Fig. 81 Company market position analysis
  • Fig. 82 Strategic framework